Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

NJBIZ publishes Health Care Power 50

The NJBIZ Health Care Power 50 list includes the CEOs of Celgene, HINJ, Johnson & Johnson, Merck and SCYNEXIS. The full list is here: https://njbiz.com/2019-njbiz-health-care-power-50/

Partners Launch New Statewide Campaign Aimed at Preventing Drug Diversion

From 6ABC Philadelphia: A new campaign about prescription drug abuse takes aim at people in New Jersey who are selling homes. The HealthCare Institute of New Jersey, N.J. Realtors, PhRMA and Partnership for a Drug-Free New Jersey announced the ‘Safe Home, Safe Sale’ campaign Feb. 19. You can read more in the NJBIZ story and on the campaign website.]

HINJ Board Chair Alex Kelly of Allergan was among the speakers at the Feb. 19 event.

 

Annual Conference Draws Healthy Crowd

The NJLSVA annual vendors conference was held on Nov. 13 at Porzio Life Sciences in Morristown. Speakers included procurement officials from Eli Lilly and Sanofi; Assemblyman Andrew Zwicker, (D-Somerset), who chairs the Assembly Science, Innovation and Technology Committee; Assemblyman Chris DePhillips (R-Bergen) a committee member; and representatives from the New Jersey Business Action Center and U.S. Small Business Administration. Despite the rainy weather and traffic tie-ups, more than 80 vendors attended. The event was moderated by Dean Paranicas, president and chief executive officer of the HealthCare Institute of New Jersey (HINJ) and organized by Haskell Berman, HINJ senior vice president, state affairs.

four guys

From Left: Haskell Berman of HINJ, Assemblymen Andrew Zwicker and Chris DePhillips and Dean Paranicas of HINJ.

2018 Regional Academic Drug Discovery Conference

The N.J. Academic Drug Discovery Consortium second annual meeting will be held Nov. 15 at Rutgers University in Piscataway. Read more and register here.

 

New Jersey’s Connected Economy: Measuring the Ripple Effect of Economic Policy

This in-depth new report from NJPRO, the New Jersey Policy Research Organization, is relevant to every industry in New Jersey, elected officials, and citizens.

Zwicker on biotech report: Public dollars, leveraged with private dollars, are key to innovation

Andrew Zwicker, who earned his Ph.D. in physics from Johns Hopkins and serves as the head of the Science Education Department of the Princeton Plasma Physics Laboratory, knows a little bit about funding. That is why the Democratic Assemblyman from the 16th District said he is optimistic about the direction the state is going. Zwicker served as vice chair of the state’s Biotechnology Task Force, which released a 44-page report June 13 on how to reinvigorate the state’s life science industry the right way.

Read more here.

The ‘State’ of New Jersey’s Innovative Industries

From New Jersey Business Magazine 

22 N.J. companies make 2018 Fortune 500 list

The annual Fortune 500 list of the nation’s biggest companies by revenue came out Monday, and 22 New Jersey companies made the cut — although only one placed in the Top 50.

That was New Brunswick-based Johnson & Johnson, which ranked 37th overall, with revenue of $76.45 billion. Newark-based Prudential Financial was the next-highest-ranked Garden State company, coming in at No. 52 with revenue of $59.69 billion.

Read more here.

With Taxpayers on the Brink, NJ Needs to Ease Off on Small Businesses

NJBIA President and CEO Michele Siekerka is urging policymakers to ease off on the litany of costly mandates and revenue raisers under consideration during this critical budget season.

In an op-ed in the Bergen Record, she observes  that Gov. Phil Murphy has proposed increasing taxes by $1.7 billion in the upcoming budget even as he prepares to sign legislation that will likely increase energy costs. This is on top of new laws ordering businesses to provide paid sick leave for all of their employees and increasing their liability in pay equity lawsuits.

Read more here.

Strong action is needed to preserve the competitiveness of America’s life-science industries

Washington D.C. – Living standards in the United States increasingly depend on the competitiveness of industries that compete internationally, particularly those that succeed by producing new innovations.

The life-science sector, which includes pharmaceuticals, biotechnology, and medical devices, is one of those industries. It is also an American success story: Our country captures more than 40 percent of the world’s major patents in both pharmaceuticals and medical devices. But as described in a new report written for the Information Technology and Innovation Foundation, the continued health of the U.S. life-sciences sector is at risk because a growing number of foreign competitors are making determined efforts to gain global market share, often using unfair tactics.

Read more here.